HEALTH TECHNOLOGY

SATO to Launch Smart Connectivity ID Solution for Healthcare Supply Chain and Hospitals

SATO | March 08, 2021

SATO, a global pioneer in labeling solutions and the development of auto-ID, launched CT4-LX-HC compact desktop printer. The purpose of the launch is to address, at the point of care and throughout the supply chain, healthcare identification needs. It will be a great help for those struggling, especially due to the global pandemic, with complicated printer settings related to healthcare services.

The smart connectivity solution of SATO incorporates feedback from front-line operators of the industry. It helps in managing label designs and make streamlined printing of labels and avoid medical incidents. Genuine SATO consumables ensure operational accuracy.  The CT4-LX-HC is also empowered with SATO’s great AEP on-board intelligence that changes the printer to a hub for coupling with outlying devices such as weight scales, thermometers, and more for modified integrations.

With COVID-19, there is a growing necessity to reinforce safety measures and confirm proper hygiene practices in daily processes to guard everyone’s well-being, whether they be customers, staff, or patients. The CT4-LX-HC features an anti-microbial casing that is antiseptic wipe down ready to safeguard hygiene when numerous users want to use its 4.3-inch touch screen exhibition in the same office.

About SATO

SATO is a global auto-ID solutions provider for leading logistics, manufacturing, food & beverage, retail, and health care companies. With a bottom-up understanding of on-site use applications, SATO tags items with identifiers to improve supply chain flows of tomorrow by solving managerial and operational challenges of today. Industry pioneers with 80 years of expertise and a 5,400+ strong global workforce in 27 countries, SATO engineer’s solutions to boost accuracy, streamline operations, provide assurance and emotional connections, support sustainability initiatives, and extending value to the consumer. For the fiscal year ending March 31, 2020, it reported revenues of JPY 116,372 million.

Spotlight

When you choose PeaceHealth Medical Group, you’re connected to an integrated health organization composed of four hospitals, numerous primary care and multispecialty care clinics, urgent care and walk-in clinics located conveniently throughout Lane County.


Other News
MEDICAL DEVICES

CeloNova Announces New Strategic Direction Focused on Creating Partnership

CeloNova BioSciences, Inc. | April 08, 2022

CeloNova BioSciences, Inc. developer and manufacturer of a portfolio of novel surfaced coated technologies, including the proprietary Polyzene™-F nanocoating, announced the strategic decision to focus its core business on creating partnership and co-development opportunities with medical device manufacturers seeking to optimize implant interaction within the body. The company's nanocoated innovation is the result of years of rigorous scientific research and engineering and has been extensively published in numerous academic articles to date. "We are pleased to offer leading medical device manufacturers access to the unique clinical advantages of our Polyzene-F nanocoated technology that has clinically demonstrated low thrombosis, restenosis and inflammation with rapid healing effects," stated Carl St. Bernard, President and Chief Executive Officer of CeloNova. "This technology offers a significant benefit to companies seeking to improve the clinical performance of their implant technologies." "I fully support CeloNova's new strategic direction which allows medical device manufacturers to benefit from long-term biocompatibility and thromboresistance of Polyzene-F. When my students and I set out to study the hemocompatibility of this inorganic polymer in our lab in Heidelberg Germany, we soon realized its potential to significantly limit a wide range of implant complications and being broadly applied in the human body and in biomedical devices." Professor Dr. Michael Grunze, Former Chair and Professor (emeritus) at the Institute of Applied Physical Chemistry of the Ruprecht-Karls-University in Heidelberg and co-inventor of Polyzene-F CeloNova is based on a rich history of medical innovation with two PzF coated medical implants successfully commercialized in the U.S. and the EU. The company's PzF coated embolic microspheres product line was sold to Boston Scientific in 2015 and the COBRA PzF NanoCoated Coronary Stent, was developed to safely and effectively treat patients who may benefit from 1-month of dual antiplatelet therapy. CeloNova's new business direction builds upon the successful application of PzF in interventional oncology and cardiology and expands its opportunities through the development of new surface coating technologies to address important unmet clinical needs. "In my pre-clinical research at CVPath since 2012, CeloNova's proprietary Polyzene-F coating has consistently demonstrated a unique advantage of allowing an implant to heal quickly and in a functional way, without the need for antiproliferative drug elution," stated Aloke Finn, MD, Medical Director and Chief Scientific Officer at CVPath and Associate Professor of Medicine at the University of Maryland. "I believe Polyzene-F will continue to play an important role in delivering safety and efficacy in clinical practice." Polyzene-F is a proprietary, ultra-pure and highly elastic surface coating possessing unique mechanical properties that allow an implant to be coated at a nanoscale level. The coating acts as a biocompatible barrier between the implant, intimal surface and circulating elements in the blood and has demonstrated thromboresistant and anti-inflammatory properties with significantly faster, higher quality healing compared to market-leading technologies.1* About CeloNova BioSciences, Inc. CeloNova BioSciences, Inc. is a global medical device company that develops, manufactures and markets novel surfaced coated technologies, including its proprietary Polyzene™-F nanocoating. The next generation nanocoating is the result of years of rigorous scientific research and engineering and has been extensively published in numerous academic articles to date.

Read More

MEDICAL DEVICES

Lark Health Builds AI-Driven Heart Health Program

Lark Health | March 17, 2022

Lark Health today announced the development of a novel AI-driven program for the prevention and management of atherosclerotic cardiovascular disease and coronary artery disease in collaboration with Roche Diagnostics. The program, named Lark Heart Health, is an AI-driven virtual care solution that provides personalized health coaching anytime, anywhere. The new Heart Health program is planned to launch later this year. Cardiovascular disease is the leading cause of death globally, and nearly half of all adults in the U.S. have some form of CVD. It's also one of the most expensive chronic conditions, with heart disease and stroke costing the U.S. healthcare system roughly $214 billion annually. Yet, provider shortages and siloed care teams leave patients with limited care options, gaps in care, and insufficient education and empowerment to self-manage their heart health. Additionally, high treatment costs and resource constraints often limit care to those with the highest acuity conditions. Built using a Cognitive Behavioral Therapy framework and designed in accordance with guidelines from the American Heart Association (AHA), Lark Heart Health will provide a cost-effective, scalable solution for continuous, person-centric remote heart health coaching intended to help users improve their healthy lifestyle behaviors, reduce stress levels, and ultimately decrease risk factors for heart disease. Through an evidence-based educational curriculum and real-time personalized coaching, Lark will provide users with the tools they need to make meaningful lifestyle changes that can help them better prevent and manage ASCVD and CAD. Earlier this year, Lark announced it had joined the AHA's Network at American Heart Association Center of Health Technology & Innovation, which is focused on building and fostering health technology relationships to develop innovative and scalable solutions. "Lark Heart Health will help those at high risk prevent and actively manage cardiovascular disease through personalized digital coaching. By leveraging our AI technology, we can deliver meaningful and engaging care at an unprecedented scale, and this collaboration with Roche Diagnostics will support the expansion of our proven tech platform into one of the costliest chronic disease markets." Julia Hu, co-founder and CEO of Lark About Lark Health Lark is a healthcare technology company aimed at delivering infinitely scalable, virtual chronic and preventative healthcare through conversational AI. To date, Lark has provided nearly 2 million people with unlimited, 24/7 personalized care delivered through an easy-to-use, text message-like interface that integrates remote patient monitoring tools and is built on a cognitive behavioral therapy framework. Lark's platform seamlessly integrates with health plans' and employers' existing healthcare infrastructure to help them scale their chronic disease prevention and management programs, boost engagement, and improve health outcomes. Lark currently works with many of the largest health plans and across four programs: Prevention, Diabetes Prevention, Diabetes Care, and Hypertension Care. Lark's Diabetes Prevention Program, which is the fastest growing and lowest cost DPP, has received the highest level of clinical recognition—Full Recognition—from the Centers for Disease Control and Prevention. The company has received numerous accolades, including having been named as one of CB Insights Digital Health 150 (2019), a finalist for the UCSF Digital Health Awards one of Fast Company's Most Innovative Companies and one of Fierce Healthcare's Fierce 15.

Read More

FUTURE OF HEALTHCARE

Spectrum Science Acquires The Seismic Collaborative, Deepening Expertise in Emerging Innovation and Health Technology

Spectrum Science | June 10, 2022

Spectrum Science, an independent, integrated marketing, communications and media agency hyper-focused on health and science, announced the acquisition of The Seismic Collaborative, an independent health and life science agency that specializes in supporting early-stage health tech and biotech companies. The Seismic acquisition establishes the Emerging Innovation Group within Spectrum, a new offering that expands the agency's capabilities to deliver at all points of a company and product lifecycle. "We're delighted to welcome Seismic's incredible talent and expertise to the Spectrum team," says Jonathan Wilson, Owner and CEO of Spectrum. "For the past several years, we've worked to strategically diversify talent and capabilities within our agency, to keep pace with client needs in a rapidly evolving industry—including the burgeoning biotech and health tech sectors. With today's acquisition, we're now able to broaden the scope of clients we support, bringing a flexible model and approach to service both early-stage and start-up clients as well as those who are more established." This new venture brings seasoned leaders with extensive experience and current business in emerging innovation and health technology to the Spectrum team, including Seismic CEO, Lisa Rodriguez, who will serve as the President of the Emerging Innovation Group within Spectrum and will play a lead role within the company's existing Health Tech practice. "Becoming a part of the Spectrum organization strengthens Seismic's connection to clients who are growing, expanding and advancing innovation in the health tech and life science sectors. Now more than ever before, emerging companies require end-to-end, global capabilities to reach their hypergrowth goals—Spectrum is the perfect place to make that happen. Our new home provides a dynamic and vibrant extension of our services where we can evolve with our client partners throughout their lifecycle." Seismic CEO Lisa Rodriguez Also joining the Spectrum organization from Seismic are EVPs Melissa Laverty and Vikki Herrera, along with Seismic's full team of strategists, writers and earned and social media specialists. Today's announcement builds on the recently announced acquisition of SONIC Health, the first deal of its kind for Spectrum in the company's 26-year history. Financing for both acquisitions was provided by Monroe Capital. About The Seismic Collaborative The Seismic Collaborative communicates the stories of the people, products and services that transform healthcare and save lives through a range of strategy, media relations, content and social media services. The Seismic Collaborative's model rejects traditional PR agency norms, focusing instead on high-touch, deeply engaged, collaborative partnerships that are structured upon the results achieved. To learn more, visit www.teamseismic.com. About Spectrum Science Spectrum Science is an integrated marketing, communications and media agency like no other. An independent, full-service agency with end-to-end capabilities, Spectrum's team are experts in science—focused on strategic engagements with our audiences. We leverage human-centered insights, motivating creative, innovative storytelling and technology to reach audiences where they are with the content they need and want. Spectrum offers global reach as the US partner and chair of Global Health Marketing & Communications (GHMC).

Read More

FUTURE OF HEALTHCARE

M1 MedTech Accelerator Program Opens Applications to Early-Stage Medical Device Companies

M1 MedTech | April 05, 2022

M1 MedTech, a medical technology accelerator sponsored by Proxima Clinical Research, a contract research organization based out of the Texas Medical Center, announcedit is accepting applications for its fall cohort. M1 MedTech is looking for five to seven of the most promising early-stage medical device companies to participate in its three-month program. The program has closed its first fund and will be selecting companies over the summer for investments up to $100,000 as a combination of both cash and in-kind services. “Our program is unique in that it combines acceleration capital, company building expertise, and the regulatory and clinical services of a top CRO,” says Larry Lawson, a venture partner and investor with M1. “Access to the M1 founders’ network, both within and outside of the Texas Medical Center, sets these companies up for success. There’s no better group to build a MedTech company with, period.” “Many MedTech companies are launched by innovative first-time founders with strong scientific and medical expertise, but who have never taken a regulated product to market or built a business. After working with so many companies at various stages of this journey to market, both with Proxima CRO and with accelerators from across the country, we realized there was a gap that needed to be filled for these rising founders. They not only need regulatory and clinical assistance from experts with hundreds of success stories in this field, we found they also need assistance with design, manufacturing, business, IP, and so much more,” says Isabella Schmitt, RAC, Director of Regulatory Affairs for Proxima CRO and Principle at M1. “These rising founders need to know what they don’t know; so, we put a lot of thought into what emerging companies and rising executives really need, and from that, we built the M1 curriculum.” M1 MedTech was created to support early-stage medical device companies, offering an immersive experience that provides tangible benefits to participating companies. The program will take on a limited number of enterprises in each cohort and offer a direct approach to helping founders advance their companies and technologies. The coaching process will include a curated educational program, interactive workshops where participants can continually build out specific company deliverables, and tailored one-on-one mentoring. “This is a very personalized program for early-stage companies focused on Class II and III medical devices,” said Sean Bittner, PhD, ACC, Director of Programs at M1 MedTech. “We’re excited to welcome our first cohort this August. The medical device companies that fit best with our program are in pre-seed or seed-stage, have completed a customer evaluation, know the issues they want to address, have not progressed far enough through the pipeline to have communicated with the FDA or completed preclinical or clinical testing,” says Bittner. “We would like the companies to have completed preliminary testing but have not gone too far into the product development phase.” “This is a fantastic opportunity for an early-stage company to receive mentoring and guidance from a group of established individuals in the life sciences industry. The hands-on 12-week workshop curriculum will cover a variety of topics including company formation and management, preclinical and clinical testing, regulatory approval, among other necessary guidance as their companies begin to mature. We are excited to aid the founders in rapidly advancing toward commercialization and prepare them for critical early investment stages.” Kevin Coker, CEO at Proxima CRO and Principal at M1 MedTech Experts from Greenlight Guru, Medrio, Galen Data, and Merge Medical Device Studio join Proxima CRO as sponsors of the program and will assist with content delivery and mentoring. Applications will remain open until May 31. About M1 MedTech M1 MedTech is an accelerator/incubator designed to build MedTech companies. The program offers capital, entrepreneurial expertise, and CRO services, as well as an immersive experience offering a hands-on approach to guide founders as they become MedTech executives and advance their companies and technologies. The coaching process includes a curated educational program with a focus on regulatory and quality dynamics, one-on-one mentoring, and interactive workshops where participants can continually build out specific company deliverables.

Read More

Spotlight

When you choose PeaceHealth Medical Group, you’re connected to an integrated health organization composed of four hospitals, numerous primary care and multispecialty care clinics, urgent care and walk-in clinics located conveniently throughout Lane County.

Resources